Evidence map›Paper›PMID 31623576›Full record

ReviewBMC nephrology2019

TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.

Yoshikuni Nagayama, Mizuki Yamano, Motoka Yagame, Tomoyuki Nariyama, Mikiko Takahashi, Masashi Kawamoto, Katsuyuki Matsui

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in BMC nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Stepwise Treatment for TAFRO Syndrome.Journal of medical cases · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Borderline Case of TAFRO Syndrome and POEMS Syndrome.Internal medicine (Tokyo, Japan) · 2021
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yoshikuni NagayamaDepartment of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan. ynaga@med.teikyo-u.ac.jp.ORCID 0000-0002-3236-9078
Mizuki YamanoDepartment of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Motoka YagameDepartment of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Tomoyuki NariyamaDepartment of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Mikiko TakahashiDepartment of Diagnostic Pathology, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Masashi KawamotoDepartment of Diagnostic Pathology, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Katsuyuki MatsuiDepartment of Internal Medicine IV, Teikyo University School of medicine, University Hospital, Mizonokuchi, Kawasaki, Japan.
Teikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTAFRO syndrome is a systemic inflammatory disorder that manifests as thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Renal dysfunction is frequently complicated with TAFRO syndrome, however, it is challenging to perform kidney biopsy in patients with TAFRO syndrome in the presence of thrombocytopenia. Renal histology in TAFRO syndrome mainly shows membranoproliferative glomerulonephritis (MPGN)-like lesions or thrombotic microangiopathy (TMA)-like glomerulopathy. We review our case and previous reports of TAFRO syndrome with kidney biopsy findings and discuss the renal pathophysiology of TAFRO syndrome. CASE PRESENTATION: We describe a previously healthy 48- year-old woman with TAFRO syndrome. Kidney biopsy performed before the treatment showed diffuse global endocapillary proliferative changes with endothelial cell swelling, double contours of partial capillary walls, and mesangiolysis, consistent with TMA-like glomerulopathy. Glucocorticoid therapy including steroid pulse was ineffective and she developed anasarca, renal dysfunction and oliguria. Hemodialysis was required. However, the anti-Interleukin (IL)-6 receptor antibody (tocilizumab) therapy was very effective. An increase in urinary volume was achieved about 2 weeks after the tocilizumab therapy and hemodialysis was discontinued. To investigate the renal pathophysiology of TAFRO syndrome, we performed immunohistological staining of vascular endothelial growth factor (VEGF)-A, CD34, and D2-40, in our case and a normal control kidney. Glomerular VEGF-A was especially positive in podocytes both, in the control and in the case, with no significant difference and there was a significant increase of VEGF-A staining area in the cortical peritubular capillaries in the case. Both glomerular and renal cortical CD34 expression were significantly decreased in our case. D2-40 expression in cortex was not significantly different.

conclusionsWe reviewed our case and other 10 previous reports about renal biopsy findings in TAFRO syndrome and found that glomerular microangiopathy was a common finding. IL-6-VEGF-axis-induced glomerular microangiopathy may play a crucial role in developing acute kidney injury in TAFRO syndrome and the anti-IL-6 receptor antibody therapy may be useful for TAFRO syndrome refractory to glucocorticoids. About the pathophysiology of VEGF in TAFRO syndrome, VEGF balance in the glomerulus and perhaps in the peritubular capillary system as well may be critical. Further investigation is needed.

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntigens, CD34CapillariesCastleman DiseaseFemaleHumansKidney DiseasesKidney GlomerulusMiddle AgedPodocytesVascular Endothelial Growth Factor AAntibodies, Monoclonal, Murine-DerivedAntigens, CD34monoclonal antibody D2-40Vascular Endothelial Growth Factor AVEGFA protein, humanCastleman diseaseInterleukin (IL)-6Membranoproliferative glomerulonephritis (MPGN)TAFRO syndromeThrombotic microangiopathy (TMA)TocilizumabVascular endothelial growth factor (VEGF)

Identifiers

PMID31623576
PMCPMC6798393
OpenAlexW2980987287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.